The market has climbed 3.2% in the last 7 days and is up 31% over the last 12 months, with earnings forecast to grow by 16% annually. For those looking to invest in smaller or newer companies, penny stocks — despite their somewhat outdated name — can still offer surprising value. In this article, we highlight several penny stocks that demonstrate financial strength and have the potential for long-term growth.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
ZJK Industrial (ZJK)	$3.09	$192.32M	✅ 3 ⚠️ 2 View Analysis >
WM Technology (MAPS)	$0.3496	$60.22M	✅ 3 ⚠️ 5 View Analysis >
LexinFintech Holdings (LX)	$2.16	$349.99M	✅ 3 ⚠️ 2 View Analysis >
Information Services Group (III)	$3.11	$198.33M	✅ 3 ⚠️ 1 View Analysis >
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	✅ 2 ⚠️ 5 View Analysis >
Niagen Bioscience (NAGE)	$4.97	$386.79M	✅ 3 ⚠️ 1 View Analysis >
Village Farms International (VFF)	$2.68	$308.48M	✅ 5 ⚠️ 1 View Analysis >
SIGA Technologies (SIGA)	$7.80	$332.43M	✅ 2 ⚠️ 1 View Analysis >
BAB (BABB)	$0.9168	$6.57M	✅ 2 ⚠️ 3 View Analysis >
Marine Petroleum Trust (MARP.S)	$4.93	$10.17M	✅ 2 ⚠️ 4 View Analysis >

Let's uncover some gems from our specialized screener.

Clover Health Investments (CLOV)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Clover Health Investments, Corp. offers Medicare Advantage plans in the United States and has a market cap of approximately $1.37 billion.

Operations: Clover Health generates revenue primarily through its insurance segment, which accounts for $1.92 billion.

Market Cap: $1.37B

Clover Health Investments recently reported a significant turnaround with a net income of US$27.33 million for Q1 2026, compared to a loss in the same period last year. The company boasts sufficient cash runway and no debt, positioning it well financially despite historical unprofitability. Clover's strategic focus on interoperability through partnerships like HealthEx enhances its Medicare Advantage offerings by empowering members with data control. However, recent insider selling and executive changes could be points of concern for investors. With earnings forecasted to grow substantially, Clover presents both opportunities and risks typical of penny stocks in this sector.

Taboola.com (TBLA)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Taboola.com Ltd. operates an artificial intelligence-based algorithmic engine platform across various countries, including Israel, the United States, and the United Kingdom, with a market cap of approximately $1.06 billion.

Operations: The company generates revenue primarily from its advertising segment, amounting to $1.91 billion.

Market Cap: $1.06B

Taboola.com Ltd. has shown a strong financial performance, reporting US$466.4 million in sales for Q1 2026, with net income of US$59.07 million, marking a significant turnaround from the previous year's loss. The company's profitability is supported by its robust advertising segment and innovative AI-driven platforms like Realize+, which enhance marketing efficiency and engagement across digital channels. Taboola's seasoned management and board provide stability, while its healthy balance sheet—with more cash than debt—adds financial resilience. Despite low return on equity at 4.7%, the company remains undervalued trading below estimated fair value, presenting potential opportunities amidst typical penny stock risks.

DiDi Global (DIDI.Y)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: DiDi Global Inc. operates a mobility technology platform offering various services in China, Brazil, Mexico, and internationally, with a market cap of approximately $16.27 billion.

Operations: The company's revenue is primarily derived from China Mobility, which generated CN¥201.92 billion, followed by International operations at CN¥14.95 billion and Other Initiatives contributing CN¥9.84 billion.

Market Cap: $16.27B

DiDi Global Inc. reported strong revenue growth, with CN¥226.70 billion for 2025, primarily from its China Mobility segment. Despite a net income of CN¥992 million, earnings growth remains negative compared to industry trends. The company has a seasoned management team and board, contributing to stability amidst legal challenges including a proposed $740 million settlement related to class action litigation in the U.S. DiDi's financial health is bolstered by short-term assets exceeding liabilities and more cash than debt, though its return on equity is low at 1%. The stock trades significantly below estimated fair value.

Turning Ideas Into Actions

• Dive into all 343 of the US Penny Stocks we have identified here.
• Seeking Other Investments? AI is about to change healthcare. These 121 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.